Page 147 - Educacional Ponenecias Congreso SEHH-STH 2020

❯ Conclusiones
El conocimiento sobre la mastocitosis, y en particular de la mastocitosis avanzada, ha aumentado constan- temente en los últimos años gracias al mayor conoci- miento biológico de la enfermedad y a la disponibili- dad de nuevas tecnologías para la detección de la mutación de KIT y de nuevas opciones terapéuticas. La detección y la cuantificación de la mutación de KIT D816V y la detección de mutaciones somáticas adicionales son muy importantes para poder realizar un buen diagnóstico y una clasificación de estos pa- cientes.
❯ Bibliografía
1. Boyce JA. Mast cells: Beyond IgE. J Allergy Clin Immunol. 2003;111(1):24-32.
2. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420-7.
3. Yarden Y, Kuang WJ,Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, et al. Hu-
man proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an
unidentified ligand. EMBO J. 1987;6(11):3341-51.
4. Besmer P. The kit ligand encoded at the murine Steel locus: a pleiotropic
growth and differentiation factor. Curr Opin Cell Biol. 1991;3(6):939-46.
5. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The proto- oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to
the mouse W locus. Nature. 1988;335(6185):88-9.
6. Furitsu T,Tsujimura T,Tono T, Ikeda H, Kitayama H, Koshimizu U, et al. Identifica-
tion of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993;92(4):1736-44.
7. Bodemer C, Hermine O, Palmérini F,Yang Y, Grandpeix-Guyodo C, Leventhal PS, et al. Pediatric mastocytosis is a clonal disease associated with D 816 v and other activating c-KIT mutations. J Invest Dermatol. 2010;130(3):804-15.
8. Martelli M, Monaldi C, De Santis S, Bruno S, Mancini M, Cavo M, et al. Recent advances in the molecular biology of systemic mastocytosis: Implications for diagnosis, prognosis, and therapy. Int J Mol Sci. 2020 Jun 2;21(11):E3987.
9. Grootens J,Ungerstedt JS,Ekoff M,Rönnberg E,Klimkowska M,Amini RM,et al. Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis. EBioMedicine. 2019;43150-8.
10. Jara-Acevedo M, Teodosio C, Sánchez-Muñoz L, Álvarez-Twose I, May- ado A, Caldas C,et al. Detection of the KIT D816V mutation in periph- eral blood of systemic mastocytosis: diagnostic implications. Mod Pathol. 2015;28(8):1138-49.
11. HoermannG,GleixnerKV,DinuGE,KundiM,GreinerG,WimazalF,etal.The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy. 2014;69(6):810-3.
12. Greiner G, Gurbisz M, Ratzinger F, Witzeneder N, Simonitsch-Klupp I, Mitter- bauer-Hohendanner G, et al. Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis. Clin Chem. 2018;64(3):547-55.
13. Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, et al. KIT mutation analysis in mast cell neoplasms: Recommenda- tions of the European Competence Network on Mastocytosis. Leukemia. 2015;29(6):1223-32.
14. Greiner G, Gurbisz M, Ratzinger F, Witzeneder N, Class SV, Eisenwort G, et al. Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis. Haematologica. 2020;105(2):366-74.
15. Muñoz-González JI, Álvarez-Twose I, Jara-Acevedo M, Henriques A, Viñas E, Prieto C, et al. Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. Blood. 2019;134(5):456-68.
16. Schwaab J, Cabral do O Hartmann N, Naumann N, Jawhar M, Weiß C, Metzgeroth G, et al. Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis. J Allergy Clin Immunol Pract. 2020. [Epub ahead of print].
17. Reiter A, George TI, Gotlib J. New developments in diagnosis, prog- nostication, and treatment of advanced systemic mastocytosis. Blood. 2020;135(16):1365-76.
18. Jawhar M, Döhner K, Kreil S, Schwaab J, Shoumariyeh K, Meggendor- fer M, et al. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. Leukemia. 2019;33(5):1124-34.
19. Jawhar M, Schwaab J, Álvarez-Twose I, Shoumariyeh K, Naumann N, Lübke J, et al. MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocyto- sis. J Clin Oncol. 2019;37(31):2846-56.
20. Pardanani A, Shah S, Mannelli F, Elala YC, Guglielmelli P, Lasho TL, et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-mo- lecular models. Blood Adv. 2018;2(21):2964-72.
21. Muñoz-Gonzalez JI, Jara-Acevedo M, Álvarez-Twose I, Merker JD, Teodosio C, Hou Y, et al. Impact of somatic and germline mutations on the outcome of systemic mastocytosis. Blood Adv. 2018;2(21):2814-28.
LXII Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia / Ponencias
147